Total Payments
$25,933
2024 Payments
$8,173
Companies
14
Transactions
46
Medicare Patients
572
Medicare Billing
$56,815
Payment Breakdown by Category
Consulting$12,150 (46.9%)
Research$7,514 (29.0%)
Travel$4,317 (16.6%)
Food & Beverage$1,363 (5.3%)
Other$506.25 (2.0%)
Education$82.44 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $12,150 | 4 | 46.9% |
| Unspecified | $7,514 | 6 | 29.0% |
| Travel and Lodging | $4,317 | 13 | 16.6% |
| Food and Beverage | $1,363 | 19 | 5.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $506.25 | 2 | 2.0% |
| Education | $82.44 | 2 | 0.3% |
Payments by Type
General
$18,418
40 transactions
Research
$7,514
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $8,214 | 3 | $0 (2024) |
| Amgen Inc. | $7,301 | 6 | $0 (2017) |
| Genentech USA, Inc. | $4,720 | 6 | $0 (2019) |
| Astellas Pharma Global Development | $2,414 | 5 | $0 (2019) |
| Medtronic, Inc. | $1,046 | 8 | $0 (2021) |
| Medtronic USA, Inc. | $1,040 | 7 | $0 (2020) |
| Servier Pharmaceuticals LLC | $506.25 | 2 | $0 (2021) |
| Celgene Corporation | $243.02 | 2 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $167.84 | 2 | $0 (2018) |
| Pharmacyclics LLC, An AbbVie Company | $108.20 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,173 | 3 | ABBVIE INC. ($8,100) |
| 2023 | $129.66 | 2 | AbbVie Inc. ($114.02) |
| 2021 | $1,552 | 10 | Medtronic, Inc. ($1,046) |
| 2020 | $179.84 | 4 | Medtronic USA, Inc. ($167.39) |
| 2019 | $8,078 | 16 | Genentech USA, Inc. ($4,720) |
| 2018 | $213.13 | 2 | Celgene Corporation ($132.52) |
| 2017 | $7,607 | 9 | Amgen Inc. ($7,301) |
All Payment Transactions
46 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | ABBVIE INC. | EPKINLY (Drug) | — | Cash or cash equivalent | $5,100.00 | Research |
| Study: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma • Category: ONCOLOGY | ||||||
| 09/30/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Food and Beverage | In-kind items and services | $73.37 | General |
| Category: ONCOLOGY | ||||||
| 07/08/2024 | ABBVIE INC. | EPKINLY (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: ONCOLOGY | ||||||
| 07/14/2023 | Abbott Laboratories | PROCLAIM (Device) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: Neuromodulation | ||||||
| 06/13/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $114.02 | General |
| Category: ONCOLOGY | ||||||
| 07/13/2021 | Medtronic, Inc. | Mazor X Stealth Edition (Device) | Travel and Lodging | In-kind items and services | $151.60 | General |
| Category: Image Guided Surgery Products | ||||||
| 07/09/2021 | Medtronic, Inc. | Mazor X Stealth Edition (Device) | Travel and Lodging | In-kind items and services | $423.26 | General |
| Category: Image Guided Surgery Products | ||||||
| 07/09/2021 | Medtronic, Inc. | Mazor X Stealth Edition (Device) | Travel and Lodging | In-kind items and services | $197.60 | General |
| Category: Image Guided Surgery Products | ||||||
| 07/09/2021 | Medtronic, Inc. | Mazor X Stealth Edition (Device) | Travel and Lodging | In-kind items and services | $197.60 | General |
| Category: Image Guided Surgery Products | ||||||
| 07/09/2021 | Medtronic, Inc. | Mazor X Stealth Edition (Device) | Food and Beverage | In-kind items and services | $27.00 | General |
| Category: Image Guided Surgery Products | ||||||
| 07/09/2021 | Medtronic, Inc. | Mazor X Stealth Edition (Device) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Image Guided Surgery Products | ||||||
| 06/15/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | In-kind items and services | $162.50 | General |
| Category: ONCOLOGY | ||||||
| 05/20/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | In-kind items and services | $343.75 | General |
| Category: ONCOLOGY | ||||||
| 05/20/2021 | Medtronic, Inc. | Mazor X Stealth Edition (Device) | Food and Beverage | In-kind items and services | $23.43 | General |
| Category: Image Guided Surgery Products | ||||||
| 01/19/2021 | Medtronic, Inc. | Mazor X Stealth Edition (Device) | Food and Beverage | In-kind items and services | $10.53 | General |
| Category: Image Guided Surgery Products | ||||||
| 11/16/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $12.45 | General |
| Category: Oncology | ||||||
| 02/14/2020 | Medtronic USA, Inc. | MazorX - Renaissance (Device) | Food and Beverage | In-kind items and services | $28.59 | General |
| Category: Enabling | ||||||
| 02/14/2020 | Medtronic USA, Inc. | MazorX - Renaissance (Device) | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: Enabling | ||||||
| 02/13/2020 | Medtronic USA, Inc. | MazorX - Renaissance (Device) | Travel and Lodging | In-kind items and services | $123.17 | General |
| Category: Enabling | ||||||
| 10/22/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $290.32 | Research |
| Study: A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation • Category: ONCOLOGY | ||||||
| 03/28/2019 | Medtronic USA, Inc. | KYPHON Balloon Kyphoplasty (Device) | Food and Beverage | In-kind items and services | $14.94 | General |
| Category: Neuro Pain (includes Interventional) | ||||||
| 03/25/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $533.33 | Research |
| Study: A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation • Category: ONCOLOGY | ||||||
| 03/25/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $517.24 | Research |
| Study: A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation • Category: ONCOLOGY | ||||||
| 03/14/2019 | Medtronic USA, Inc. | KYPHON Balloon Kyphoplasty (Device) | Food and Beverage | In-kind items and services | $8.62 | General |
| Category: Neuro Pain (includes Interventional) | ||||||
| 03/07/2019 | Medtronic USA, Inc. | StealthStation (Device) | Travel and Lodging | In-kind items and services | $652.82 | General |
| Category: Image Guided Surgery Products | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | ABBVIE INC. | $5,100 | 1 |
| A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation | Astellas Pharma Global Development | $2,414 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 3 | 168 | 234 | $51,228 | $15,038 |
| 2020 | 7 | 404 | 665 | $158,100 | $41,777 |
Total Patients
572
Total Services
899
Medicare Billing
$56,815
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 106 | 148 | $29,156 | $8,013 | 27.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 42 | 62 | $18,352 | $6,312 | 34.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 20 | 24 | $3,720 | $713.46 | 19.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 208 | 382 | $74,294 | $21,409 | 28.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 94 | 148 | $43,097 | $11,743 | 27.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 24 | 24 | $9,864 | $2,996 | 30.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 40 | $11,840 | $2,793 | 23.6% |
| 38222 | Bone marrow biopsy and aspiration | Facility | 2020 | 16 | 18 | $11,801 | $1,043 | 8.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 30 | 31 | $4,710 | $973.12 | 20.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 20 | 22 | $2,494 | $821.07 | 32.9% |
About Dr. Robert Stuart, MD
Dr. Robert Stuart, MD is a Hematology & Oncology healthcare provider based in Charleston, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467560409.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Stuart, MD has received a total of $25,933 in payments from pharmaceutical and medical device companies, with $8,173 received in 2024. These payments were reported across 46 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($12,150).
As a Medicare-enrolled provider, Stuart has provided services to 572 Medicare beneficiaries, totaling 899 services with total Medicare billing of $56,815. Data is available for 2 years (2020–2021), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Charleston, SC
- Active Since 08/29/2006
- Last Updated 10/22/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1467560409
Products in Payments
- EPKINLY (Drug) $8,100
- Blincyto (Biological) $7,301
- VENCLEXTA (Biological) $4,720
- XOSPATA (Drug) $2,414
- Mazor X Stealth Edition (Device) $1,046
- StealthStation (Device) $849.29
- TIBSOVO (Drug) $506.25
- MazorX - Renaissance (Device) $167.39
- Revlimid (Drug) $132.52
- VENCLEXTA (Drug) $114.02
- Imbruvica (Drug) $108.20
- RYDAPT (Drug) $87.23
- TASIGNA (Drug) $80.61
- WELIREG (Drug) $73.37
- KYPHON Balloon Kyphoplasty (Device) $23.56
- PROCLAIM (Device) $15.64
- XPOVIO (Drug) $12.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Charleston
Mr. George Geils, M.d, M.D
Hematology & Oncology — Payments: $184,021
Hematology & Oncology $184,021
Mr. David Ellison, M.d, M.D
Hematology & Oncology — Payments: $39,035
Hematology & Oncology $39,035
Dr. Albert Lockhart, Md, MD
Hematology & Oncology — Payments: $36,997
Hematology & Oncology $36,997
Dr. Irl Greenwell, M.d, M.D
Hematology & Oncology — Payments: $30,803
Hematology & Oncology $30,803
Dr. Brian Lingerfelt, Md, MD
Hematology & Oncology — Payments: $30,721
Hematology & Oncology $30,721
Dr. George Keogh, M.d, M.D
Hematology & Oncology — Payments: $18,248
Hematology & Oncology $18,248